Creative Medical Technology Holdings, Inc. Selling, General and Administrative Expense
Creative Medical Technology Holdings, Inc. (CELZ) reported Selling, General and Administrative Expense of $1.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-07
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $1.08M, a 47.64% increase year-over-year.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $888.64K, a 0.03% increase year-over-year.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $1.37M, a 1.89% decline year-over-year.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $776.82K, a 55.80% increase year-over-year.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for fiscal 2025 was $3.76M, a 16.18% increase from fiscal 2024.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for fiscal 2024 was $3.24M, a 9.02% decline from fiscal 2023.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for fiscal 2023 was $3.56M, a 9.72% decline from fiscal 2022.
- Creative Medical Technology Holdings, Inc. selling, general and administrative expense for fiscal 2022 was $3.94M, a 33.03% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.08M 10-Q · filed 2026-08-07 | $1.97M 10-Q · filed 2026-08-07 | $3.34M derived: sum of 3 quarters · filed 2026-08-07 | $4.11M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $888.64K 10-Q · filed 2026-05-08 | $2.26M derived: sum of 2 quarters · filed 2026-05-08 | $3.03M derived: sum of 3 quarters · filed 2026-05-08 | $3.76M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $2.14M derived: sum of 2 quarters · filed 2026-03-20 | $2.88M derived: sum of 3 quarters · filed 2026-08-07 | $3.76M 10-K · filed 2026-03-20 |
| 2025-09-30 | $776.82K 10-Q · filed 2025-11-07 | $1.51M derived: sum of 2 quarters · filed 2026-08-07 | $2.40M 10-Q · filed 2025-11-07 | $3.79M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $731.52K 10-Q · filed 2026-08-07 | $1.62M 10-Q · filed 2026-08-07 | $3.01M derived: sum of 3 quarters · filed 2026-08-07 | $3.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $888.40K 10-Q · filed 2026-05-08 | $2.28M derived: sum of 2 quarters · filed 2026-05-08 | $2.78M derived: sum of 3 quarters · filed 2026-05-08 | $3.46M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.89M derived: sum of 2 quarters · filed 2026-03-20 | $2.57M derived: sum of 3 quarters · filed 2026-03-20 | $3.24M 10-K · filed 2026-03-20 |
| 2024-09-30 | $498.61K 10-Q · filed 2025-11-07 | $1.17M derived: sum of 2 quarters · filed 2025-11-07 | $1.85M 10-Q · filed 2025-11-07 | $3.24M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $676.09K 10-Q · filed 2025-08-08 | $1.35M 10-Q · filed 2025-08-08 | $2.75M derived: sum of 3 quarters · filed 2025-08-08 | $3.28M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $671.48K 10-Q · filed 2025-05-09 | $2.07M derived: sum of 2 quarters · filed 2025-05-09 | $2.60M derived: sum of 3 quarters · filed 2025-05-09 | $3.46M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $1.93M derived: sum of 2 quarters · filed 2025-03-14 | $2.79M derived: sum of 3 quarters · filed 2025-03-14 | $3.56M 10-K · filed 2025-03-14 |
| 2023-09-30 | $531.04K 10-Q · filed 2024-11-08 | $1.39M derived: sum of 2 quarters · filed 2024-11-08 | $2.16M 10-Q · filed 2024-11-08 | $3.06M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $859.54K 10-Q · filed 2024-08-09 | $1.63M 10-Q · filed 2024-08-09 | $2.53M derived: sum of 3 quarters · filed 2024-08-09 | $3.34M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $771.02K 10-Q · filed 2024-05-10 | $1.67M derived: sum of 2 quarters · filed 2024-05-10 | $2.48M derived: sum of 3 quarters · filed 2024-05-10 | $3.58M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $899.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $1.71M derived: sum of 2 quarters · filed 2024-03-22 | $2.81M derived: sum of 3 quarters · filed 2024-03-22 | $3.94M 10-K · filed 2024-03-22 |
| 2022-09-30 | $805.46K 10-Q · filed 2023-11-14 | $1.91M derived: sum of 2 quarters · filed 2023-11-14 | $3.04M 10-Q · filed 2023-11-14 | $4.47M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.11M 10-Q · filed 2023-08-11 | $2.24M 10-Q · filed 2023-08-11 | $3.67M derived: sum of 3 quarters · filed 2023-08-11 | $4.42M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.13M 10-Q · filed 2023-05-12 | $2.56M derived: sum of 2 quarters · filed 2023-05-12 | $3.32M derived: sum of 3 quarters · filed 2023-05-12 | $3.81M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.19M derived: sum of 2 quarters · filed 2023-03-31 | $2.68M derived: sum of 3 quarters · filed 2023-03-31 | $2.96M 10-K · filed 2023-03-31 |
| 2021-09-30 | $757.24K 10-Q · filed 2022-11-10 | $1.26M derived: sum of 2 quarters · filed 2022-11-10 | $1.54M 10-Q · filed 2022-11-10 | $1.85M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $498.32K 10-Q · filed 2022-08-12 | $779.24K 10-Q · filed 2022-08-12 | $1.10M derived: sum of 3 quarters · filed 2022-08-12 | $1.38M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $280.92K 10-Q · filed 2022-05-13 | $596.72K derived: sum of 2 quarters · filed 2022-05-13 | $881.82K derived: sum of 3 quarters · filed 2022-05-13 | $1.10M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $315.79K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $600.89K derived: sum of 2 quarters · filed 2022-03-30 | $815.78K derived: sum of 3 quarters · filed 2022-03-30 | $1.16M 10-K · filed 2022-03-30 |
| 2020-09-30 | $285.10K 10-Q · filed 2021-11-15 | $499.99K derived: sum of 2 quarters · filed 2021-11-15 | $846.15K 10-Q · filed 2021-11-15 | $1.16M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $214.89K 10-Q · filed 2021-08-16 | $561.05K 10-Q · filed 2021-08-16 | $872.09K derived: sum of 3 quarters · filed 2021-08-16 | $1.19M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $346.17K 10-Q · filed 2021-05-17 | $657.21K derived: sum of 2 quarters · filed 2021-05-17 | $974.84K derived: sum of 3 quarters · filed 2021-05-17 | $1.29M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $311.04K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $628.67K derived: sum of 2 quarters · filed 2021-03-17 | $941.25K derived: sum of 3 quarters · filed 2021-03-17 | $1.22M 10-K · filed 2021-03-17 |
| 2019-09-30 | $317.64K 10-Q · filed 2020-11-13 | $630.21K derived: sum of 2 quarters · filed 2020-11-13 | $912.18K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $312.57K 10-Q · filed 2020-08-14 | $594.55K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $281.97K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $1.05M 10-K · filed 2020-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |